Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TACTICS: Cross-over Comparison of Tofogliflozin vs Empagliflozin on NT-proBNP in Type 2 Diabetes
jRCTs031190021Completed
- Sponsor
- Kowa Company, Ltd.
- Start
- Aug 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised trial of tofogliflozin and empagliflozin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Kowa Company, Ltd. Primary endpoint: NT-proBNP. Started Aug 2019; status: completed.
02
Drugs
tofogliflozinempagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on jRCTs031190021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031190021.